High-Power MRI reveals hidden brain changes in Parkinson's

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients will be included: * suffering from idiopathic Parkinson's disease according to UKPDSBB criteria (Gibb \& Lees, 1988; Hughes et al., 1992), * the stage of the disease is I-II according to the Hoehn and Yahr scale, * which do not receive dopaminergic treatment, * duration of disease development 5 years, * without major cognitive impairment (Moca \> 24) * men or women aged 18 to 75, * having understood and signed the informed consent form, * members of a social security scheme. Controls: * subjects male or female aged 18 -75 years * subjects affiliated to a social security scheme. * volunteers who have given their written consent. Exclusion Criteria: Patients will be excluded: * having a severe tremor (\> 3 for a trembling sub-item of UPDRS 3) making the MR examination impossible, * patients with "contra-indications" to an MRI exam (without administration of a gadolinium chelate): presence of metal parts in the body (electronic devices such as a pacemaker, a neurostimulator, a cochlear implant, prostheses, etc.), claustrophobia, * taking any treatment that may interact with brain concentrations of neurotransmitters, such as all psychotropic drugs and in particular antidepressants, neuroleptics, benzodiazepines, antiepileptics, * pregnant women, * treated by deep brain neurostimulation, * patients under guardianship or guardianship or protection of justice, * patients who are excluded from another study. Controls: * persons suffering from progressive neurological and psychiatric pathology, * persons with "contra-indications" to an MRI examination (without administration of a gadolinium chelate): presence of metal parts in the body (electronic devices such as a pacemaker, a neurostimulator, a cochlear implant, prostheses, etc.), claustrophobia, * taking any treatment that may interact with brain concentrations of neurotransmitters, such as: all psychotropic drugs and in particular antidepressants, neuroleptics, benzodiazepines, antiepileptics, * pregnant women, * persons under guardianship or trusteeship or protection of justice, * people who are excluded from another study.